Isotretinoin - Nova Laboratories
Alternative Names: 13 cis retinoic acid; 13-CRALatest Information Update: 25 Dec 2021
At a glance
- Originator Nova Biopharma
- Developer Nova Laboratories
- Class Anti-inflammatories; Antiacnes; Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Neuroblastoma
Most Recent Events
- 17 Mar 2021 Isotretinoin is still in phase I/II trials for Neuroblastoma (In infants, In neonates, In children, In adults, In adolescents) in United Kingdom (PO)
- 04 Jan 2019 Chemical structure information added
- 17 Apr 2018 Phase-I/II clinical trials in Neuroblastoma (In infants, In neonates, In children, In adults, In adolescents) in United Kingdom (PO) (NCT03291080) (EudraCT2016-005104-25)